Table 1.
Baseline patient and disease characteristics
|
RCC Cohort N = 39 |
GC Cohort N = 46 |
CRC Cohort N = 50 |
|
|---|---|---|---|
| Median age (range), years | 62 (40–81) | 58 (35–77) | 64 (32–81) |
| ≥ 65 years, n (%) | 16 (41) | 11 (24) | 25 (50) |
| Male, n (%) | 31 (79) | 34 (74) | 29 (58) |
| Race, n (%)a | |||
| White | 32 (82) | 32 (70) | 18 (36) |
| Black or African American | 0 | 1 (2) | 1 (2) |
| Asian | 7 (18) | 12 (26) | 31 (62) |
| ECOG performance status, n (%) | |||
| 0 | 12 (31) | 11 (24) | 9 (18) |
| 1 | 27 (69) | 35 (76) | 41 (82) |
| Time from initial diagnosis to start of treatment, median (range), months | 33 (8–151) | 13 (3–121) | 38 (12–121) |
| Metastatic sites of disease, n (%) | |||
| 0 | 0 | 1 (2) | 0 |
| 1 | 7 (18) | 11 (24) | 7 (14) |
| 2 | 14 (36) | 19 (41) | 16 (32) |
| > 2 | 18 (46) | 15 (33) | 27 (54) |
| Sites of metastasis, n (%) | |||
| With metastases | 39 (100) | 45 (98) | 50 (100) |
| Bone | 12 (31) | 6 (13) | 6 (12) |
| Liver | 9 (23) | 25 (54) | 30 (60) |
| Lung | 25 (64) | 12 (26) | 38 (76) |
| Lymph node | 20 (51) | 26 (57) | 31 (62) |
| Peritoneal | 6 (15) | 20 (43) | 12 (24) |
| Number of prior regimens, n (%) | |||
| 1 | 11 (28) | 34 (74) | 0 |
| 2 | 13 (33) | 9 (20) | 19 (38) |
| 3 | 12 (31) | 3 (7) | 20 (40) |
| 4 | 3 (8) | 0 | 11 (22) |
CRC colorectal adenocarcinoma, ECOG Eastern Cooperative Oncology Group, GC gastric adenocarcinoma, RCC renal cell carcinoma
aOne patient in the GC cohort declined to answer/race unknown